This page shows the latest Ontruzant news and features for those working in and with pharma, biotech and healthcare.
MSD launches EU’ s first biosimilar Herceptin in UK. Ontruzant is set to be strong competition for Roche’s blockbuster. ... The first biosimilar version of Roche’s blockbuster breast cancer drug Herceptin has been launched in the UK by MSD under
But Roche’s cancer antibody isn’t its only drug battling for market share - breast cancer blockbuster Herceptin (trastuzmab) also has a biosimilar rival in the form of Samsung Bioepis’Ontruzant,
First Herceptin biosimilar cleared in Europe. Ontruzant is approved for all the same indications as Roche’s blockbuster. ... Ontruzant is the fourth biosimilar developed by the Korean company to receive marketing authorisation in the EU.
The CHMP recommended approval of two biosimilars, namely Samsung Bioepis' Ontruzant (trastuzumab) - the first biosimilar of Roche's breast cancer therapy Herceptin to get a positive opinion in the EU - and
Ontruzant is set to be strong competition for Roche’s blockbuster. .
More from news
Approximately 4 fully matching, plus 1 partially matching documents found.
Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...